Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
06 Nov 2019  |  North America
Strategic Collaborations and Stakeholder Awareness Along with Clear Paths to Commercialization will Play a Key Role for Success in the Human Microbiome Market
Interest in the microbiome as a science and industry has exploded over the past decade. Innovations are happening across 3 significant categories for human health benefits: microbiome-based therapeutics, over-the-counter (OTC) dietary supplements, and self-diagnostics/screening. The OTC market is the largest because of the lack of precise regulatio...
04 Nov 2019  |  North America
An End-user Perspective on Laboratory Spending Reveals Modest 2020 Budget Increases Following Healthier 2019 Spending
Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2019 that centered around the state of their laboratories in 2019 and their expectations for 2020. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year...
26 Sep 2019  |  Global
Exploring Key Investment Trends, Companies-to-Action, and Growth Opportunities for AI in the Pharmaceutical Industry
Pharmaceutical drug discovery and development processes suffer from declining success rates and a stagnant pipeline. Artificial Intelligence (AI) supported by Big Data could be a key element that can provide an effectual solution. There has been a rapid growth in the data generated within the life sciences and pharmaceutical industries. This stems ...
23 Sep 2019  |  North America
A Measurement System to Spark Companies 2 Action (C2A)—Innovation That Fuels New Deal Flow and Growth Pipelines
The immunoassay and clinical chemistry market is the highest share contributor for the total in vitro diagnostics (IVD) market. Globally valued at $28.7 billion in 2019, this market segment contributes 37.6% of the total IVD market of $76.3 billion. Within the high-medium to low analyzer segment, there are over 40 companies globally. Of these, 14 c...
20 Sep 2019  |  Global
Therapeutic Outcomes Optimization
Therapeutically more effective drugs for the treatment of chronic diseases represents a crucial need. Biosimilars and biobetters offer the possibility to lower the cost of treating a variety of chronic diseases. In particular, biosimilars are the less expensive option; however, biobetters have demonstrated to be more effective, even over longer per...
20 Sep 2019  |  Global
A Review of Advances in Cell Therapies, Antibodies, Fusion Proteins, and Other Innovative Approaches for Cancer Treatment
There are numerous companies developing immunotherapy approaches to treat cancer, autoimmune and several other diseases. Current study describes some of the recent advances in immunotherapy, mostly cancer. These include refined cell therapies, stem cell applications in cancer treatment, monoclonal, polyclonal and bispecific antibodies. Some of exci...
03 Sep 2019  |  North America
Clinical Applications for Single Cell Analysis Remain a Heavily Uncontested Market Place
Single cell genomic and proteomics tools have gained significant importance in the past 2 years. The year 2018 was particularly very active with a lot of platforms made available by both established life sciences tools companies and start-ups. 10X Genomics and Fluidigm have demonstrated the potential for high-throughput single cell applications. Th...
27 Aug 2019  |  North America
Digital Solutions will Spark Integrated Development Approaches and Successful Adjunctive Therapies for Disease Modification
As one lives longer, one needs to increasingly battle age-related disorders. Neurodegenerative disorders are the most worrisome, because they impact millions of people around the world and lack any curative therapy. While companies continue their search, they are also battling declining revenues from marketed products used to manage symptoms. Heavy...
23 Aug 2019  |  South Asia, Middle East & North Africa
Increased Local Manufacturing and Government Spending on Lifestyle Diseases to be Key Driving Factors in 2020
In this research deliverable, Frost & Sullivan’s analyst team provides bold perspectives and predictions for the Middle East and North Africa (MENA) region’s life sciences industry in 2020. The markets covered include pharmaceuticals, biotechnology, and in-vitro diagnostics. The analysis captures the impact of trends that are expected to transp...
25 Jun 2019  |  Global
Translating Technology Innovation to Market Competitiveness
Overall Impact of Biomanufacturing Technology Innovations Impact on Unmet Needs Pharmaceutical companies perceive analytical services as important. There is a need for a robust platform that enables the provision of such services. Pharma firms are outsourcing crucial processes and are utilizing services such as analytics, research, process developm...